Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heyan Kuntai Capsules in women with diminished ovarian reserve or poor ovarian response undergoing IVF-ET
ChiCTR2300073418Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China
- Start
- May 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of Kuntai and somatropin in Diminished Ovarian Reserve (DOR), poor ovarian response (POR) and infertility (2 arms), sponsored by The First Affiliated Hospital of University of Science and Technology of China. Primary endpoint: Number of oocytes retrieved. Planned start May 2023; status: not yet recruiting.
02
Drugs
Kuntaisomatropin
03
Conditions
Diminished Ovarian Reserve (DOR)poor ovarian response (POR)infertility
Beyond the preview
Go deeper on ChiCTR2300073418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073418.